uniQure (NASDAQ:QURE) Shares Gap Down – What’s Next?

Shares of uniQure (NASDAQ:QURE) gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with a volume of 41,727 shares changing hands.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of uniQure in a research report on Tuesday, December 10th. Mizuho raised their price target on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Wednesday, December 11th. Cantor Fitzgerald raised their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Finally, Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $33.88.

uniQure Trading Up 1.2 %

The stock has a market capitalization of $890.05 million, a PE ratio of -3.68 and a beta of 0.89. The stock’s 50 day moving average price is $10.15 and its 200-day moving average price is $7.52. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. On average, sell-side analysts expect that uniQure will post -3.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. RTW Investments LP bought a new stake in uniQure in the third quarter worth $49,000. China Universal Asset Management Co. Ltd. grew its stake in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new stake in shares of uniQure in the 3rd quarter worth about $53,000. Quarry LP purchased a new stake in shares of uniQure during the 3rd quarter valued at about $58,000. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,306 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.